prazosin
Trade name: minipress
Approved
Jun 23, 1976
Prazosin (trade names Minipress, Vasoflex, Lentopres, and Hypovase) is a selective α-1-adrenergic receptor antagonist used to treat hypertension. Prazosin acts by inhibiting the postsynaptic alpha-1-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases. The antihypertensive characteristics of prazosin make it a second-line choice for the treatment of high blood pressure. Prazosin is also useful in treating urinary hesitancy associated with prostatic hyperplasia, blocking alpha-1 receptors, which control constriction of both the prostate and urethra. Although not a first line choice for either hypertension or prostatic hyperplasia, it is a choice for patients who present with both problems concomitantly. Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea. Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, nervousness, and rash. — NCATS
Clinical trial activity
65 trials · 59 clinical orgs · 17 marketing orgs
Earliest trial started Nov 1, 2000 (NCT00450164)
Timeline
1970s
- Jun 23, 1976
Earliest FDA Approval
1980s
- Sep 12, 1988
Teva — Marketing Organization
- Jan 11, 1989
Watson Pharmaceuticals — Marketing Organization
- Feb 28, 1989
Mylan — Marketing Organization
- Mar 15, 1989
DAVA Pharmaceuticals — Marketing Organization
- Apr 10, 1989
Ani Pharmaceuticals — Marketing Organization
- Apr 10, 1989
IDT Australia Ltd. — Marketing Organization
2000s
2010s
- Oct 3, 2018
Novitium Pharma — Marketing Organization
2020s
- Dec 23, 2021
Granules India — Marketing Organization
- Oct 21, 2022
Appco Pharma — Marketing Organization
- Dec 30, 2022
Mankind Pharma — Marketing Organization
- Mar 6, 2023
Alembic — Marketing Organization
- Mar 31, 2023
Aurobindo Pharma — Marketing Organization
- Jan 3, 2024
Lannett Company, Inc. — Marketing Organization
- Sep 17, 2024
MSN Laboratories — Marketing Organization
Indications
Approved for
Studied for
- Alcoholism · Phase 4
- Alcohol Withdrawal Delirium · Phase 1/Phase 2
- Alzheimer Disease · Phase 2
- Anxiety · Phase 1
- Anxiety Disorders · Phase 1
- Atherosclerosis · Phase 4
- Blood Pressure · Phase 2
- Brain Concussion · Phase 1/Phase 2
- Cannabis · Phase 4
- Cardiovascular Diseases · Phase 1
- Cerebrovascular Circulation · Phase 2
- Cigarette Smoking · Early Phase 1
- Combat Disorders · Phase 1/Phase 2
- COVID-19 · Phase 2
- Dementia · Phase 4
- Dreams · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Fibrosis · Phase 4
- Gastrointestinal Hemorrhage · Phase 4
- Headache · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 1
- Hepatitis C, Chronic · Phase 2
- Hypertension · Phase 4
- Hypertension, Portal · Phase 4
- Kidney Calculi · Phase 3
- Magnetic Resonance Imaging · Phase 2
- Marijuana Abuse · Phase 4
- Methamphetamine · Phase 2
- Migraine Disorders · Phase 1/Phase 2
- Morals · Phase 4
- Nicotine · Phase 1
- Pheochromocytoma · Phase 2
- Post-Concussion Syndrome · Phase 1/Phase 2
- Post-Traumatic Headache · Phase 4
- Problem Behavior · Phase 2
- Prostatic Hyperplasia · Phase 4
- Rhinitis · Phase 4
- Rhinitis, Allergic · Phase 4
- Scorpion Stings · Phase 3
- Sleep Wake Disorders · Phase 3
- Stress Disorders, Post-Traumatic · Phase 4
- Stress Disorders, Traumatic, Acute · Phase 2
- Stress, Psychological · Phase 2
- Suicidal Ideation · Phase 4
- Tachyphylaxis · Phase 4
- Tobacco Use Disorder · Phase 2
- Urinary Bladder, Neurogenic · Phase 1/Phase 2
Mechanism of action
- Adrenergic receptor alpha-1ANTAGONIST
Adrenergic receptor alpha-1 antagonist
Combination products
minizide
with polythiazide
Approval history
- approvedPriority reviewJun 23, 1976
Chemistry & pharmacology
SMILES
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC- Mol. weight
- 383.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2 ↗
- WikipediaPrazosin ↗
- NCATSXM03YJ541D ↗
- ChEMBLCHEMBL1558 ↗
Also known as
- 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
- 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
- 2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
- 2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
- alphavase 0.5
- alphavase 1
- alphavase 2
- alphavase 5
- cp-12299
- cp-12299
- cp-122991
- cp-122991
- cp-12299-1
- cp-12299-1
- furazosin
- hypovase
- hypovase
- hypovase b.d.
- kentovace
- minipress
- minipress
- minipress
- minipress xl
- minipress xl
- prazosin
- prazosin
- prazosin
- prazosin
- prazosin
- prazosin
- prazosin
- prazosin
- prazosin
- prazosin
- prazosina
- prazosina
- prazosin clorhidrato
- prazosine
- prazosine
- prazosine
- prazosin hcl
- prazosin hcl
- prazosin hcl
- prazosin hydrochloride
- prazosin hydrochloride
- prazosin hydrochloride
- prazosin hydrochloride
- prazosinum
- prazosinum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07231978 | Phase 1 | Nov 14, 2025 | Pfizer |
| NCT06629090 | Phase 2 | Jan 31, 2025 | University of Wisconsin |
| NCT06629077 | Phase 2 | Jan 31, 2025 | National Institute of Neurological Disorders and Stroke (NINDS), University of Wisconsin |
| NCT06147622 | Phase 1 | Feb 29, 2024 | Kinnov Therapeutics |
| NCT06287905 | Phase 4 | Feb 1, 2023 | Sohag University |
| NCT05189977 | Phase 1 | Aug 22, 2022 | IQVIA, Otsuka |
| NCT04967443 | Phase 1 | Sep 22, 2021 | Pfizer |
| NCT04793685 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2021 | Yale University |
| NCT04721353 | Phase 4 | Nov 9, 2020 | University of Washington |
| NCT04365257 | Phase 2 | May 13, 2020 | Fast Grants, Johns Hopkins University |
| NCT04108104 | Phase 2 | Oct 31, 2019 | ECSOR, Kinnov Therapeutics |
| NCT03997864 | Phase 4 | Jul 31, 2019 | University of Colorado, Denver |
| NCT03710642 | Phase 2 | Jul 30, 2019 | Department of Veteran Affairs, National Institute on Aging (NIA) |
| NCT04320589 | Phase 2 | Jun 30, 2019 | Cairo University, National Cancer Institute, Egypt |
| NCT03894345 | Phase 1 | May 24, 2019 | University of Manitoba |
| NCT03539614 | Phase 3 | Jun 4, 2018 | Department of Veteran Affairs |
| NCT03416569 | N/A | Mar 31, 2018 | University of Maryland |
| NCT03010995 | Phase 1 | May 15, 2017 | University of Louisville |
| NCT03045016 | Phase 2 | Feb 1, 2017 | University of Lyon |
| NCT03221751 | Phase 4 | Dec 1, 2016 | Department of Veteran Affairs |
Organizations
Research & Development (59)
Marketing (20)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alembic | For profit | MKTG | Mar 6, 2023 |
| Am Therap | For profit | MKTG | — |
| Ani Pharmaceuticals | For profit | MKTG | Apr 10, 1989 |
| Ani Pharmaceuticals | For profit | SYN | Apr 10, 1989 |
| Appco Pharma | For profit | MKTG | Oct 21, 2022 |
| Aurobindo Pharma | For profit | MKTG | Mar 31, 2023 |
| DAVA Pharmaceuticals | For profit | MKTG | Mar 15, 1989 |
| Granules India | For profit | MKTG | Dec 23, 2021 |
| IDT Australia Ltd. | For profit | MKTG | Apr 10, 1989 |
| Lannett Company, Inc. | For profit | MKTG | Jan 3, 2024 |
| MSN Laboratories | For profit | MKTG | Sep 17, 2024 |
| Mankind Pharma | For profit | MKTG | Dec 30, 2022 |
| Mylan | For profit | MKTG | Feb 28, 1989 |
| Novitium Pharma | For profit | MKTG | Oct 3, 2018 |
| Pfizer | For profit | NDA | — |
| Pfizer | For profit | SYN | Jun 23, 1976 |
| Puracap Pharmaceutical | For profit | MKTG | — |
| Teva | For profit | MKTG | Sep 12, 1988 |
| Teva | For profit | SYN | Sep 12, 1988 |
| Watson Pharmaceuticals | For profit | MKTG | Jan 11, 1989 |